SG11201407412QA - Method of prevention of neurological diseases - Google Patents
Method of prevention of neurological diseasesInfo
- Publication number
- SG11201407412QA SG11201407412QA SG11201407412QA SG11201407412QA SG11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA SG 11201407412Q A SG11201407412Q A SG 11201407412QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- drive
- priestly
- carlsbad
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655742P | 2012-06-05 | 2012-06-05 | |
PCT/US2013/043927 WO2013184591A1 (en) | 2012-06-05 | 2013-06-03 | Method of prevention of neurological diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407412QA true SG11201407412QA (en) | 2014-12-30 |
Family
ID=49712532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407412QA SG11201407412QA (en) | 2012-06-05 | 2013-06-03 | Method of prevention of neurological diseases |
Country Status (13)
Country | Link |
---|---|
US (1) | US10258632B2 (ko) |
EP (1) | EP2841060A4 (ko) |
JP (1) | JP2015518887A (ko) |
KR (1) | KR20150023292A (ko) |
CN (1) | CN104379136A (ko) |
AU (1) | AU2013271841B2 (ko) |
CA (1) | CA2875330A1 (ko) |
HK (1) | HK1201741A1 (ko) |
IL (1) | IL235736B (ko) |
MX (1) | MX2014014993A (ko) |
RU (1) | RU2014153894A (ko) |
SG (1) | SG11201407412QA (ko) |
WO (1) | WO2013184591A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3055548B1 (fr) | 2016-09-05 | 2018-09-28 | Metabrain Research | Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire |
CN106265685A (zh) * | 2016-09-18 | 2017-01-04 | 南通大学 | 没药甾酮z在制备抗抑郁症药物中的应用 |
CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
EP3659593A1 (en) * | 2018-11-30 | 2020-06-03 | Forschungszentrum Jülich GmbH/ Abteilung RP-PT | Trmt2a inhibitors for use in the treatment of polyglutamine diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002193818A (ja) * | 2000-12-22 | 2002-07-10 | Council Scient Ind Res | ググリピッドの新規使用法:認知エンハンサー、抗高血糖性の、及び皮膚の状態に関するものとして |
KR101166000B1 (ko) * | 2002-01-28 | 2012-07-16 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
WO2006024947A2 (en) | 2004-09-02 | 2006-03-09 | Neuro Therapeutics Ab | Methods and materials relating to enhanced production of dopamine neurons |
US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
WO2010088400A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
-
2013
- 2013-06-03 JP JP2015516096A patent/JP2015518887A/ja active Pending
- 2013-06-03 KR KR20147033073A patent/KR20150023292A/ko not_active Application Discontinuation
- 2013-06-03 AU AU2013271841A patent/AU2013271841B2/en active Active
- 2013-06-03 US US14/397,981 patent/US10258632B2/en active Active
- 2013-06-03 WO PCT/US2013/043927 patent/WO2013184591A1/en active Application Filing
- 2013-06-03 RU RU2014153894A patent/RU2014153894A/ru not_active Application Discontinuation
- 2013-06-03 CN CN201380026036.0A patent/CN104379136A/zh active Pending
- 2013-06-03 MX MX2014014993A patent/MX2014014993A/es unknown
- 2013-06-03 EP EP13800837.0A patent/EP2841060A4/en not_active Withdrawn
- 2013-06-03 SG SG11201407412QA patent/SG11201407412QA/en unknown
- 2013-06-03 CA CA2875330A patent/CA2875330A1/en not_active Abandoned
-
2014
- 2014-11-17 IL IL235736A patent/IL235736B/en not_active IP Right Cessation
-
2015
- 2015-03-06 HK HK15102320.0A patent/HK1201741A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2014153894A (ru) | 2016-08-10 |
US10258632B2 (en) | 2019-04-16 |
HK1201741A1 (en) | 2015-09-11 |
AU2013271841B2 (en) | 2018-03-08 |
IL235736A0 (en) | 2015-01-29 |
CA2875330A1 (en) | 2013-12-12 |
CN104379136A (zh) | 2015-02-25 |
MX2014014993A (es) | 2015-06-17 |
KR20150023292A (ko) | 2015-03-05 |
JP2015518887A (ja) | 2015-07-06 |
IL235736B (en) | 2020-06-30 |
EP2841060A4 (en) | 2016-02-24 |
US20150094289A1 (en) | 2015-04-02 |
AU2013271841A1 (en) | 2014-11-27 |
WO2013184591A1 (en) | 2013-12-12 |
EP2841060A1 (en) | 2015-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201407200TA (en) | Liquid formulation | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy |